FOLSOM, Calif., Dec. 12, 2017 -- Visionary Integration Professionals (VIP) announced the successful launch of a project whose scope included consulting, system integration and deployment of the Bureau of Cannabis Control Online Licensing Application System.
VIP brought deep experience in the deployment of the Accela Civic Platform, a cloud-based, commercial-off-the-shelf (COTS) regulatory solution, to the project which also included cloud-based COTS products and world-class website design. VIP leveraged an Agile/SCRUM approach due to an accelerated project timeline.
“The entire team from VIP successfully met the challenge of implementing the Bureau’s licensing system,” said Bureau Chief Lori Ajax. “This was a tremendous effort and we are very excited to launch our on-line licensing system for commercial cannabis activity in California.” The project went live ahead of the CA legislative deadline of January 1, 2018.
The online system manages the process within the State of California for the application of commercial cannabis licenses by distributors, microbusinesses, testing laboratories, retailers and cannabis events.
Applicants may now apply online for both temporary and annual commercial cannabis licenses, track the status of an existing application and submit payments. The licensing portal may be accessed online here: http://online.bcc.ca.gov/.
“It was a historic moment in the nation when California voters passed Proposition 64,” said Jonna Ward CEO of VIP. “VIP is honored to play a significant part in that history.”
About VIP
Visionary Integration Professionals (VIP) provides industry-leading management consulting, system integration, and technology deployment solutions. VIP helps its clients strengthen mission outcomes by combining deep industry specialization, agility to adapt as needed, and an unwavering commitment to client satisfaction. VIP brings expertise in how to deploy systems that align people, processes, and technology to accelerate strategic change and to deliver business results in partnership with its clients. Since 1996, VIP has worked with nearly 1,000 state and local, federal, and commercial clients. To learn more about VIP, please visit: www.trustvip.com
Media Notes:
For information on commercial cannabis licenses for manufacturing, visit the California Department of Public Health website: www.cdph.ca.gov/mcsb.
For information on a commercial cannabis license for cultivation, visit to the California Department of Food and Agriculture (CDFA) website: http://calcannabis.cdfa.ca.gov/.
For information about the licensing application process, visit: http://www.bcc.ca.gov/.
For information on all three licensing authorities, visit the state's California Cannabis Portal: cannabis.ca.gov.
Media Contact John Carmean [email protected]


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 



